Business
Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering
MILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to address serious unmet medical needs, today announced the pricing of its upsized initial public offering of 21,177,600 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Eikon has granted the underwriters a 30-day option to purchase up to an additional 3,176,6
About this update from Eikon Therapeutics, Inc.
[{"type":"image","alt":"Eikon Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Eikon Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":194,"url":"https://media.zenfs.com/en/globenewswire.com/4244084826f1ce90c788c046545dcf21"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QdEnUJyKXyPJ33ritDiLtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4244084826f1ce90c788c046545dcf21","width":300,"height":194}},"lazy":false},{"type":"text","content":"MILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to address serious unmet medical needs, today announced the pricing of its upsized initial public offering of 21,177,600 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Eikon has granted the underwriters a 30-day option to purchase up to an additional 3,176,640 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The gross proceeds to Eikon from the offering, without giving effect to the underwriters’ option to purchase additional shares and before deducting underwriting discounts and commissions and offering expenses payable by Eikon, are expected to be approximately $381 million.","length":882,"tagName":"p"},{"type":"text","content":"Eikon’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 5, 2026 under the ticker symbol “EIKN”. The offering is expected to close on or about February 6, 2026, subject to the satisfaction of customary closing conditions.","length":261,"tagName":"p"},{"type":"text","content":"J.P. Morgan, Morgan Stanley, BofA Securities, Cantor, and Mizuho are acting as joint book-running managers for the offering.","length":124,"tagName":"p"},{"type":"text","content":"A registration statement on Form S-1 (File No. 333-292633) relating to the offering has been filed with the Securities and Exchange Commission (the “SEC”) and was declared effective on January 30, 2026.","length":202,"tagName":"p"},{"type":"text","content":"The offering of the shares is being made only by means of a prospectus forming part of the effective registration statement relating to t...